Cormorant Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Cormorant Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-296,712	Closed	-$4.48M	–	65
2018 Q4	$4.48M	Buy	+296,712	New	+$4.4M	0.36%	49
2017 Q4	–	Sell	-100,000	Closed	-$1.82M	–	54
2017 Q3	$1.82M	Sell	100,000 -130,000	-57%	-$2.03M	0.32%	46
2017 Q2	$3.56M	Hold	230,000	–	–	0.59%	44
2017 Q1	$3.97M	Sell	230,000 -141,636	-38%	-$1.86M	0.58%	46
2016 Q4	$4.08M	Hold	371,636	–	–	0.55%	45
2016 Q3	$5.83M	Hold	371,636	–	–	0.64%	47
2016 Q2	$3.8M	Buy	371,636 +613	+0.2%	+$6.99K	0.54%	49
2016 Q1	$4.79M	Hold	371,023	–	–	0.72%	42
2015 Q4	$7.74M	Buy	+371,023	New	+$5.87M	0.93%	36

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Cormorant Asset Management's CTMX Position: Q1 2019 in Review

Cormorant Asset Management sold out of CytomX Therapeutics (CTMX) in Q1 2019, closing a stake of 296,712 shares — an estimated $4.48M sold.

Cormorant Asset Management first reported a position in CTMX in Q4 2015 and held it in 9 quarters. The position peaked at $7.74M in Q4 2015. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

Cormorant Asset Management reported no remaining CytomX Therapeutics position as of Q1 2019 after selling out during the quarter.
Cormorant Asset Management sold 296,712 CytomX Therapeutics shares in Q1 2019, an estimated $4.48M.
Cormorant Asset Management first reported a position in CytomX Therapeutics in Q4 2015 and held it in 9 quarters.
Cormorant Asset Management's CytomX Therapeutics position peaked at $7.74M in Q4 2015.
113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.